Table 1. Baseline characteristics.
| N = 44 | % | |
|---|---|---|
| Age (years) | 60.8 (34-79) | |
| Sex F:M | 27:17 | 61.4: 38.6 |
| Size (cm) | 4.6 (1.1-11.5) | - |
| Histology | ||
| Papillary | 31 | 70.5 |
| Follicular | 12 | 27.2 |
| Poorly differentiated | 1 | 2.3 |
| Follicular variant papillary | 6 | 13.6 |
| Hürthle Cell | 3 | 6.8 |
| Insular | 3 | 6.8 |
| Tall cell | 1 | 2.3 |
| 8th edition AJCC | ||
| Tx | 21 | 47.8 |
| T1a | 0 | 0 |
| T1b | 0 | 0 |
| T2 | 6 | 13.6 |
| T3a | 4 | 9.0 |
| T3b | 1 | 2.3 |
| T4a | 7 | 15.9 |
| T4b | 5 | 11.4 |
| Nx | 31 | 70.5 |
| N0 | 1 | 2.3 |
| N1a | 4 | 9.0 |
| N1b | 8 | 18.2 |
| M1 | 23 | 52.2 |
| At least one RAI treatment | 41 | 93.2 |
| RAI activity (mCi) | 422.5 (150-1000) | - |
| Symptoms before MKI | 20 | 45.5 |
| Time from diagnosis to MKI (years) | 68.7 (0.3-210.1) | - |
| Additional therapy besides MKI | ||
| External beam radiation | 27 | 61.4 |
| Chemotherapy | 3 | 6.8 |
| Embolization | 3 | 6.8 |
| Zoledronate | 6 | 13.6 |
| Final status | ||
| Stable disease | 11 | 25 |
| Complete response | 1 | 2.3 |
| Progression | 7 | 15.9 |
| Disease related death | 25 | 56.8 |
| PFS on MKI (months) | 24 (10.2-37.7) | - |
| OS after MKI (months) | 31 (17.7-44-.2) | - |
| Follow up (months) | 99.6 (12.5-236.3) | - |
MKI: multikinase inhibitors; PFS: progression free survival; OS: overall survival; RAI: radioiodine.